Side-by-side financials for BRNS and JNJ. Every figure below comes from audited SEC filings and refreshed market data.
| Metric | BRNS | JNJ |
|---|---|---|
| Market cap | - | $573.71 B |
| US-listed rank | - | #20 |
| Revenue (latest FY) | $0.00 | $94.19B |
| Net income (latest FY) | -$66.43M | $26.80B |
| Net margin | - | 28.5% |
| P/E (trailing FY) | - | 21.4 |
| SEC filings | 247 | 984 |
In their latest fiscal years, Barinthus Biotherapeutics plc. reported $0.00 in revenue while JOHNSON & JOHNSON reported $94.19B.
Full pages: Barinthus Biotherapeutics plc. and JOHNSON & JOHNSON, or browse the full rankings.